Novartis AG Increase Decrease In Cash And Cash Equivalents
Novartis AG (NVSEF) reported Increase Decrease In Cash And Cash Equivalents of -$24.00 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-02-04.
Financial Statements › Notes
ifrs-full:IncreaseDecreaseInCashAndCashEquivalents · last filed 2026-02-04
- Novartis AG increase decrease in cash and cash equivalents for the quarter ending 2025-06-30 was -$410.00M.
- Novartis AG increase decrease in cash and cash equivalents for the quarter ending 2024-06-30 was -$1.57B.
- Novartis AG increase decrease in cash and cash equivalents for the quarter ending 2023-06-30 was -$1.11B.
- Novartis AG increase decrease in cash and cash equivalents for the quarter ending 2022-06-30 was -$10.23B, a 877.13% decline year-over-year.
| Period end | Increase Decrease In Cash And Cash Equivalents 3 month | Increase Decrease In Cash And Cash Equivalents 6 month | Increase Decrease In Cash And Cash Equivalents 12 month |
|---|---|---|---|
| 2025-12-31 | -$24.00M 20-F · filed 2026-02-04 | ||
| 2025-06-30 | -$410.00M 6-K · filed 2025-07-17 | -$4.80B 6-K · filed 2025-07-17 | |
| 2024-12-31 | -$1.93B 20-F · filed 2026-02-04 | ||
| 2024-06-30 | -$1.57B 6-K · filed 2025-07-17 | -$5.49B 6-K · filed 2025-07-17 | |
| 2023-12-31 | $5.88B 20-F · filed 2026-02-04 | ||
| 2023-06-30 | -$1.11B 6-K · filed 2024-07-18 | $3.37B 6-K · filed 2024-07-18 | |
| 2022-12-31 | -$4.89B 20-F · filed 2025-01-31 | ||
| 2022-06-30 | -$10.23B 6-K · filed 2023-07-18 | -$8.78B 6-K · filed 2023-07-18 | |
| 2021-12-31 | $2.75B 20-F · filed 2024-01-31 | ||
| 2021-06-30 | $1.32B 6-K · filed 2022-07-19 | -$4.54B 6-K · filed 2022-07-19 | |
| 2020-12-31 | -$1.45B 20-F/A · filed 2023-05-15 | ||
| 2020-06-30 | $1.39B 6-K · filed 2021-07-21 | -$5.20B 6-K · filed 2021-07-21 | |
| 2019-12-31 | -$2.16B 20-F · filed 2022-02-02 | ||
| 2019-06-30 | $3.18B 6-K · filed 2020-07-21 | -$3.28B 6-K · filed 2020-07-21 | |
| 2018-12-31 | $4.41B 20-F · filed 2021-01-26 | ||
| 2018-06-30 | $6.63B 6-K · filed 2019-07-18 | $3.59B 6-K · filed 2019-07-18 | |
| 2017-12-31 | $1.85B 20-F · filed 2020-01-29 | ||
| 2017-06-30 | $284.00M 6-K · filed 2018-07-18 | $849.00M 6-K · filed 2018-07-18 | |
| 2016-12-31 | $2.33B 20-F · filed 2019-01-30 | ||
| 2015-12-31 | -$8.35B 6-K · filed 2018-01-24 |